Clinical Trials

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects


Study ID
Diffusion Pharma 100-206

NCT Number
NCT03393000 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0629

Principle Investigator
Dr. Samuel Goldlust

Phase
III

Sponsor
Diffusion Pharma


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now